Unity Biotechnology, Inc.
UBXUnlisted companyUnity Biotechnology, Inc. in brief
Unity Biotechnology, Inc. is an unlisted company in the Biotechnology industry, based in California, USA. It was founded in 2011. In its latest reported year it had sales of $0 M and a net loss of $94 M.
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Unity Biotechnology, Inc.
Unity Biotechnology, Inc. was a publicly traded American biotechnology company that develops drugs that target senescent cells. The company ceased operations in 2025.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Unity Biotechnology, Inc. timeline
- 2011
- 🏁· approximateFounded
- 2018
- 🔔· approximateInitial public offering on Nasdaq
Events of Unity Biotechnology, Inc. from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Unity Biotechnology, Inc.
- Acquisitions and changes
- No longer listed: ticker UBX is not in the SEC's, the US exchanges' or FINRA's lists of traded securities (checked 14 November 2026).
Market cap history
World rank over time
Rank in USA: #2,771 (Jan 2020) · #3,008 (Jan 2021) · #4,476 (Jan 2022) · #4,934 (Dec 2022) · #4,840 (Jul 2023) · #4,232 (Jan 2024)
Annual results
- Revenue
- $0 M
- Operating income
- —
- Net income
- $-94 M
Markets and events: Unity Biotechnology, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 5,500 shares at $0.30
- : 3,595 shares at $0.34
- : 1,024 shares at $0.79
- : 7,229 shares at $0.79
- : 522 shares at $0.80
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
H-1B hiring at Unity Biotechnology, Inc.#
4 labor condition applications certified in fiscal 2020 for 4 positions, at a median wage of $88 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| SENIOR RESEARCH ASSOCIATEMolecular and Cellular Biologists | 2 | $79 K |
| ScientistMolecular and Cellular Biologists | 1 | $96 K |
| Senior Manager, Project ManagementNatural Sciences Managers | 1 | $159 K |
Where: South San Francisco, CA 4
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as UNITY BIOTECHNOLOGY, INC.
How Unity Biotechnology, Inc. compares in Biotechnology
- Revenue$0 M · higher than 0% of 647
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Unity Biotechnology, Inc.🇺🇸 | $33 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Profile updated:
- Nov 14, 2026
Figures from value.today research, Wikipedia.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Unity Biotechnology, Inc.? Verify and update this profile — free
Show Unity Biotechnology, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.